Xultophy® 100/3.6 is a once-daily injectable to improve glycemic control for adults with type 2 diabetes as an adjunct to diet and exercise.1 Xultophy® 100/3.6 is a combination drug consisting of liraglutide, a long-acting glucagon-like peptide-1 receptor agonist, and insulin degludec, a long-acting basal insulin.1
Frequently asked questions about Xultophy® 100/3.6
Xultophy® 100/3.6 consists of two molecules that work together throughout the body to control blood sugar for a full 24 hours.
These components are insulin and GLP-1 RA. Insulin helps muscle, liver, and fat cells absorb and retain glucose from the bloodstream for energy. GLP-1 RA activity prevents processes that can cause sugar fluxes.
- In the gut, it slows down the rate at which glucose enters the bloodstream
- In the pancreas, it helps beta cells release insulin, but only when blood glucose is high
- When blood glucose is high, GLP-1 acts on alpha cells in the pancreas in ways that prevent the liver from releasing glucose